ARTICLE | Clinical News

Pexastimogene devacirepvec: Additional Phase Ib data

July 27, 2015 7:00 AM UTC

Additional data from an open-label, dose-escalation, Korean Phase Ib trial in 15 mCRC patients who failed previous treatment with standard chemotherapy showed that 1x10 6, 1x10 7 and 3x10 7 pfu/kg IV Pexa-Vec once every 2 weeks for 8 weeks led to 10 cases of stable disease. Pexa-Vec led to a progression-free survival (PFS) of 61 days and overall survival (OS) of 10.3 months. No dose-limiting toxicities (DLTs) were reported and the MTD was not reached. The most common adverse event was grade 1/2 flu-like symptoms. Data were published in Molecular Therapy. ...